Brief: MeiraGTx Reports Q4, Annual Financial, Operational Results

MeiraGTx Holdings

14/03/2023 13:22

March 14 (Reuters) - MeiraGTx Holdings Plc  MGTX.O :
    * MEIRAGTX REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL AND
OPERATIONAL RESULTS
    * ON TRACK FOR BLA SUBMISSION OF BOTARETIGENE SPAROPARVOVEC
FOR
TREATMENT OF XLRP IN 2024
    * ON TRACK FOR BLA SUBMISSION OF BOTARETIGENE SPAROPARVOVEC
FOR
TREATMENT OF XLRP IN 2024
    * CASH AND CASH EQUIVALENTS WERE $115.5 MILLION AS OF
DECEMBER 31,
2022, COMPARED TO $137.7 MILLION AS OF DECEMBER 31, 2021
    * NET LOSS  FOR YEAR ENDED DECEMBER 31, 2022, WAS $129.6
MILLION,
OR $2.87 BASIC AND DILUTED NET LOSS PER ORDINARY SHARE
    * FY2022 EARNINGS PER SHARE VIEW $-2.74 -- REFINITIV IBES
DATA
    * WILL HAVE SUFFICIENT CAPITAL TO FUND OPERATING EXPENSES
AND
CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 OF 2024

Source text for Eikon:  ID:nGNXtH5Lw 
Further company coverage:  MGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))